Bioventus Inc. $BVS Stake Boosted by Bailard Inc.

Bailard Inc. increased its position in shares of Bioventus Inc. (NYSE:BVS) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,800 shares of the company’s stock after acquiring an additional 7,100 shares during the period. Bailard Inc.’s holdings in Bioventus were worth $250,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of BVS. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Bioventus in the 1st quarter worth about $143,000. Royce & Associates LP grew its stake in shares of Bioventus by 21.8% in the 1st quarter. Royce & Associates LP now owns 892,216 shares of the company’s stock valued at $8,164,000 after buying an additional 159,980 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Bioventus by 35.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after buying an additional 4,513 shares during the last quarter. Mackenzie Financial Corp raised its position in Bioventus by 27.3% during the first quarter. Mackenzie Financial Corp now owns 41,090 shares of the company’s stock valued at $376,000 after acquiring an additional 8,824 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Bioventus by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,554,224 shares of the company’s stock valued at $23,371,000 after acquiring an additional 92,143 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Insider Transactions at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 17,701 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $7.42, for a total transaction of $131,341.42. Following the transaction, the director directly owned 56,997 shares of the company’s stock, valued at $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 33.00% of the company’s stock.

Bioventus Stock Performance

BVS stock opened at $7.35 on Friday. The firm has a 50 day moving average of $6.98 and a two-hundred day moving average of $6.87. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $12.61. The company has a market capitalization of $608.31 million, a price-to-earnings ratio of -12.05 and a beta of 0.80. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.